anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The constellation of fevers accompanied by headache and vomiting is a red flag for clinicians that appropriately triggers evaluation for meningitis and other life-threatening diagnoses. When symptoms persist even after these conditions are ruled out, patient care becomes more challenging. We present the case of a 6-year-old male with a history of autism spectrum disorder who presented with 6 months of headaches and associated vomiting and intermittent fevers with negative infectious workup despite cerebrospinal fluid pleocytosis. Serial neuroimaging and laboratory evaluation ultimately led to a diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) presenting as aseptic meningitis. The clinical and radiographic findings of MOGAD are widely variable and overlap with several other inflammatory conditions, which makes diagnosis challenging. This case highlights the importance of recognizing this rare MOGAD presentation as an infectious meningitis mimic.
Promethazine is useful for:

Perennial and seasonal allergic rhinitis. Vasomotor rhinitis. Allergic conjunctivitis due to inhalant allergens and foods. Mild, uncomplicated allergic skin manifestations of urticaria and angioedema. Amelioration of allergic reactions to blood or plasma. Dermographism. Anaphylactic reactions, as adjunctive therapy to epinephrine and other standard measures, after the acute manifestations have been controlled. Preoperative, postoperative, or obstetric sedation. Prevention and control of nausea and vomiting associated with certain types of anesthesia and surgery. Therapy adjunctive to meperidine or other analgesics for control of post-operative pain. Sedation in both children and adults, as well as relief of apprehension and production of light sleep from which the patient can be easily aroused. Active and prophylactic treatment of motion sickness. Antiemetic therapy in postoperative patients.
Analgesic and antipyretic compositions comprise paracetamol and a diffusion factor i.e. an enzyme characterized by its depolymerizing action on hyaluronic acid and/or chondroitin-sulphuric acid, namely, hyaluromidase or sulphochondroitinase.  A barbiturate e.g. phenobarbital and/or an antihistamine e.g. promethazine may be incorporated in the compositions, which are usually administered in the form of suppositories, the excipients being a glyceride and perfume e.g. pine needle oil.
The invention belongs to the technical field of traditional Chinese medicine, and provides a medicament for treating lichen planus in order to solve the problem of the treatment of lichen planus. The medicament is prepared from Rehmannia glutinosa Libosch, the stem of noble dendrobium, Radix Scutellariae, Forsythia suspensa, honeysuckle, Zaocys dhumnades, notopterygium root, Schizonepeta, radix sileris, manyleaf meadowure rhizome and root, Salvia miltiorrhiza, eupolyphaga, radix sophorae flavescentis, cicada slough, cortex dictam and Rhizoma Atractylodis Macrocephalae according to a certain proportion. The above drugs are mixed and decocted with 600 ml of water to obtain a first dosage of 200 ml, and 500 ml of water is added and decocted with the drugs to obtain a second dosage of 200 ml. The medicament should be taken with empty stomach twice a day in the morning and in the evening. Among the traditional Chinese medicines employed in the invention, Zaocys dhumnades, notopterygium root, Schizonepeta, radix sileris and manyleaf meadowure rhizome and root relive wind and eliminate dampness; Rehmannia glutinosa Libosch, the stem of noble dendrobium, Radix Scutellariae, Forsythia suspensa and honeysuckle nourish yin and clear heat; Salvia miltiorrhiza and eupolyphaga invigorate blood circulation and transform blood stasis; and radix sophorae flavescentis, cicada slough, cortex dictam and Rhizoma Atractylodis Macrocephalae invigorate spleen and relieve itching. The above drugs in compatibility play a synergic effect and has very good effect in the treatment of lichen planus.
Synovial sarcoma (SS) is identified as a sarcoma with monomorphic blue spindle cells that display variable epithelial differentiation and is characterized by the SS18::SSX fusion gene. SS accounts for approximately 5-10% of all soft tissue sarcomas, making it a relatively common type within this group of tumors. Since SS is generally sensitive to chemotherapy, the standard treatment for SS includes extensive surgical resection, complemented by neoadjuvant chemotherapy with several approved anticancer drugs. However, in advanced and metastatic cases, the efficacy of these drugs is limited, resulting in poor prognoses. This underscores the need for innovative therapeutic strategies. Patient-derived cancer cell lines are essential tools for basic and preclinical research, yet only four SS cell lines are publicly available. To facilitate the studies of SS, we have developed a novel SS cell line, named NCC-SS6-C1, derived from surgically excised tumor tissue of an SS patient. NCC-SS6-C1 cells preserve the SS18::SSX1 fusion gene, consistent with the genetic characteristics of the original tumor. The cells exhibit continuous proliferation, invasiveness, and the ability to form spheroids. Additionally, we confirmed that this cell line was useful for evaluating the efficacy of anticancer drugs. Our results suggest that NCC-SS6-C1 is a useful tool for basic and pre-clinical studies of SS.
Japanese and Caucasian participants will receive INS1007 at Dose 3 or matching placebo, orally, up to Day 30 in Part A under fasted conditions. Enrollment will commence in this cohort once the safety and tolerability data in Cohort 2 is deemed acceptable by the principal investigator (PI) and the Sponsor's medical monitor.
Subjects will receive a single 10 mg hard capsule of Orfadin (Reference) in treatment period 1, 10 mg tablet of Nitisinone 10 mg Tablet (Test Product 1) in treatment period 2, and 10 mg tablet of Nitisinone 10 mg Tablet High Compritol (Test Product 2) in treatment period 3 under fasting conditions. Each treatment period will be separated by at least 23 calendar days of washout period.
FARYDAK can cause fetal harm when administered to a pregnant woman. Panobinostat was teratogenic in rats and rabbits. If FARYDAK is used during pregnancy, or if the patient becomes pregnant while taking FARYDAK, the patient should be apprised of the potential hazard to the fetus [see Use in Specific Populations (8.1, 8.3)].

Advise females of reproductive potential to avoid becoming pregnant while taking FARYDAK. Advise sexually-active females of reproductive potential to use effective contraception while taking FARYDAK and for at least 3 months after the last dose of FARYDAK.

Advise sexually active men to use condoms while on treatment and for 6 months after their last dose of FARYDAK [see Use in Specific Populations (8.3)].
Following screening and assessment of rescue medication use, subjects will receive one tablet of placebo 35 mg orally twice daily with food for 52 weeks during treatment period. Placebo will be dispensed to subjects at the study visits.
PROBLEM TO BE SOLVED: To provide an antibiotic which exhibit fast effects.SOLUTION: The present invention relates to antibiotics. This antibiotic comprises gnetin C, resveratrol, vitamin E and a fluidization agent. The percentage by weight of gnetin C is between 0.17 weight% and 4.11 weight%. The percentage by weight of resveratrol is between 0.06 weight% and 1.33 weight%. The percentage by weight of vitamin E is between 0.28 weight% and 2.22 weight%. It is preferable for the percentage by weight of gnetin C to be between 0.17 weight% and 1.37 weight%. In this case it is preferable for the percentage by weight of resveratrol to be between 0.06 weight% and 0.44 weight%. It is preferable for the sum of percentage by weight of gnetic C and the percentage by weight of resveratrol to be between 0.23 weight% and 1.81 weight%.SELECTED DRAWING: Figure 4
Disclosed is a health-care information management system that utilizes modular and reusable software objects to allow for user configuration. The disclosed information management system allows for the creation by the user software objects representative of specific events and resources which will occur or be utilized during the provision of health-care to patients. These user configured software modules then allow the user to track the provision of health-care, the utilization of resources during the provision of health-care, the allocation of resources to perform medical procedures and identify opportunities for enhancing efficiencies in the provision of health-care services. In on embodiment of the invention described, the system allows for the user to create, manage and maintain software modules representing specific clinical pathways to be performed in a health-care institution. The user creates these modules using user configurable software objects that function to represent containers, resources and data. The software objects are modular and re-usable and allow the user to select components for creation of the modules. The created modules may then be used to provide information management relating to the provision of the medical procedures represented by the clinical pathway modules.
The Vitality Wellness program is the incentive-based wellness initiative of Discovery Health Medical Aid Scheme, a national private health insurer in South Africa. The standard program includes membership to three national gym chains, which is subsidized to 80% of the normal monthly subscription cost. Members have the opportunity to earn points by attending gyms, which contribute, together with points earned from engagement in other wellness and preventive activities, to tier status (Blue, Bronze, Silver, Gold and Diamond). Tier status allows members to receive increasing discounts on a range of goods and services from commercial partners. Enrollment into the trial took place for a period of 5 months, and the intervention took place over a period of 12 months following registration.
Background: Singing is a multimodal activity that requires physical, cognitive and psychosocial performance, with benefits in various domains of health and well-being of older adults. In recent years, research has increasingly studied group singing as an important cost-effective intervention to promote active and healthy aging. However, the specific factors responsible for these benefits need further experimental support, as most studies do not allow for causal inferences. This study responds to the need for further randomized controlled trials (RCT), with follow-up measurement, on the benefits of group singing in older adults with diverse socioeconomic status. Also, while most studies often focus on specific outcome measures dimensions, in this study, the conjoint effects of physical, psychosocial, emotional and cognitive dimensions are analyzed, testing mediation and moderation effects of psychosocial and cognitive variables in the health and well-being of the participants. Methods: The team implements and measures the effects of a singing group program for older adults, with an RCT design, in a natural context, before and after the intervention and in a follow-up, four months after the intervention. Participants: 140 retired older adults (\> 60 years), users of a social care institution, were invited to participate in a singing group program and randomly allocated to an experimental intervention group (n = 70), and a control (n = 70) group enrolled in the regular activities proposed by the institution. The intervention consists of 34 bi-weekly group singing sessions, of two-hours each, for four months. Measures on social and emotional well-being, cognitive function, and health indicators (as blood pressure, glycemia, cholesterol, c-reactive protein, erythrocyte sedimentation rate, respiratory function, body balance, body activity, sleep quality, medication intake, and health services attendance) will be collected. Interviews on the motivation and perceived benefits of participation will also be collected. Discussion: Significant improvements are expected in the outcome measures in the experimental group after the intervention, in comparison with the control group and the pretest, validating the singing group program as a cost-effective intervention for healthy aging. Psychoemotional, psychosocial and cognitive variables are expected to be mediators of the effects of the program on the health and well-being of the participants.
The present invention generally relates to a new approach for the therapy of allergic responses, based on targeted elimination of cells expressing the Fc Epsilon RI receptor by a chimeric cytotoxin Fc2'-3-PE40. A sequence encoding amino acids 301-437 of the Fc region of the mouse IgE molecule was genetically fused to PE40 - a truncated form of PE lacking the cell binding domain. The chimeric protein, produced in Escherichia coli, specifically and efficiently kills mouse mast cell lines expressing the Fc Epsilon RI receptor, as well as primary mast cells derived from bone marrow. The present invention provides a chimeric protein for targeted elimination of Fc Epsilon RI expressing cells especially useful for the therapy of allergic responses. The said chimeric protein comprised of a cell targeting syncretizing for Fc Epsilon RI expressing cells is prepared. The present invention also provides pharmaceutical compositions, for the treatment of allergic diseases and for the treatment of hyperplasias and malignancies, comprising as an active ingredient the above mentioned chimeric protein and a conventional adjuvant product.
Participants receive five weeks individual robotic gait training in LOPES II, targeting paretic propulsion (60 minutes, two time a week). The robotic gait training is complemented with daily home exercises (15 minutes/day) focusing on increasing strength and practice of learned strategies in daily life.
The efficacy and safety of tavaborole topical solution was evaluated in two multicenter, double-blind, randomized, vehicle-controlled trials. Tavaborole topical solution or vehicle was applied once daily for 48 weeks in subjects with 20% to 60% clinical involvement of the target toenail, without dermatophytomas or lunula (matrix) involvement.

A total of 1194 subjects (795 tavaborole topical solution, 399 Vehicle) 18 to 88 years of age, 82% male, 84% white, participated in these two trials. Efficacy assessments were made at 52 weeks following a 48-week treatment period.

The Complete Cure efficacy endpoint included negative mycology (negative KOH wet mount and negative fungal culture) and Completely Clear Nail (no clinical evidence of onychomycosis as evidenced by a normal toenail plate, no onycholysis, and no subungual hyperkeratosis). Efficacy results from the two trials are summarized in Table 2.

a. Complete cure defined as 0% clinical involvement of the target toenail plus negative KOH and negative culture.

b. Complete or almost complete cure defined as ≤10% affected target toenail area involved and negative KOH and culture.

c. Mycologic cure defined as negative KOH and negative culture.
The invention provides a novel osmotic pump isosorbide mononitrate quick-controlled release tablet. A single-chamber osmotic pump controlled release tablet is taken as a controlled release part; a quick release part is a quick release layer coated outside the osmotic pump controlled release tablet; and the ratio of the quick release tablet and the controlled release tablet is 3:7. In the osmotic pump controlled release tablet part, ethyl cellulose (EC) and polyvidone (PVP) are taken as semi-permeable membrane forming materials, and are coated on the surface of a medicament table core, so that the phenomenon of ageing of a semi-permeable membrane can be avoided, and medicament residues are reduced. The invention further provides a method for improving the anti-ageing performance of the osmotic pump isosorbide mononitrate quick-controlled release tablet. The method is characterized in that: ethyl cellulose-polyvidone is taken as a semi-permeable membrane material. Moreover, the invention further provides an application of an ethyl cellulose-polyvidone composition to preparation of an osmotic pump isosorbide mononitrate quick-controlled release tablet with anti-ageing performance.
The epidural analgesia is initiated by a manual bolus of the epidural solution (ropivacaine 1 mg/ml fentanyl 2.5 mug/ml) 10 + 10 ml and then continued by automated boluses of the same solution (6ml every 40 minutes) with possibility for the parturient to administer 6 ml extra doses with a 20 minute lock-out. Maximum hourly dose 20 ml.
CRNDE is considered an oncogene expressed as long non-coding RNA. Our previous paper is the only one reporting CRNDE as a micropeptide-coding gene. The amino acid sequence of this micropeptide (CRNDEP) has recently been confirmed by other researchers. This study aimed at providing a mass spectrometry (MS)-based validation of the CRNDEP sequence and an investigation of how the differential expression of CRNDE(P) influences the metabolism and chemoresistance of ovarian cancer (OvCa) cells. We also assessed cellular localization changes of CRNDEP, looked for its protein partners, and bioinformatically evaluated its RNA-binding capacities. Herein, we detected most of the CRNDEP sequence by MS. Moreover, our results corroborated the oncogenic role of CRNDE, portraying it as the gene impacting carcinogenesis at the stages of DNA transcription and replication, affecting the RNA metabolism, and stimulating the cell cycle progression and proliferation, with CRNDEP being detected in the centrosomes of dividing cells. We also showed that CRNDEP is located in nucleoli and revealed interactions of this micropeptide with p54, an RNA helicase. Additionally, we proved that high CRNDE(P) expression increases the resistance of OvCa cells to treatment with microtubule-targeted cytostatics. Furthermore, altered CRNDE(P) expression affected the activity of the microtubular cytoskeleton and the formation of focal adhesion plaques. Finally, according to our in silico analyses, CRNDEP is likely capable of RNA binding. All these results contribute to a better understanding of the CRNDE(P) role in OvCa biology, which may potentially improve the screening, diagnosis, and treatment of this disease.
FIELD: medicine. SUBSTANCE: claimed invention describes arylidene and heteroarylideneoxinedole of formula (I):wherein Y is bicycle ring selected from naphthalene, tetraline, quinoline and isoquinoline; R is hydrogen or oxo(= O) group when Y is naphthalene, quinoline or isoquinoline; each of Rand Ris independently hydrogen, C-C--alkyl or C-C- alkanoyl; m is 0.1 or 2; n is 0, 1, 2 or 3; each of Rand Ris independently hydrogen, halogen, cyano, C-C-alkyl, carboxy, nitro or -NRR, wherein each of Rand Ris independently hydrogen or C-C- alkyl; Ris hydrogen or C-C-alkyl, and pharmaceutically acceptable salts. Said derivatives are useful as tyrosinekinase inhibitors. The claimed invention also describes process for preparation of said derivatives and drugs useful in antitumor therapy. The claimed invention also describes process for preparing drug by mixing active component and pharmaceutically acceptable carriers and/or diluents. EFFECT: improved properties of the title compounds, improved properties of the drug and more efficient preparation process.
PURPOSE:To make possible the measurement of the refined protein specific to the rheumatism by using the refined protein antibody specific to the rheumatism having a specific mol.wt., isoelectric point and mobility. CONSTITUTION:The precipitate salted out by salted. Ammonium sulfate of the about 25-35% of the rheumatism patient's plasma is subjected to ion exchange chromatography such as, for example, 'DEAE-Sephadex A-5O(R)' and after the refraction eluted at a low salt concn. is removed, the fraction eluted thereafter is recovered. The protein A derived from, for example, an antihuman IgG antibody or staphylococcus is conjugated by such a gas as 'sepharose 4B(R)' by ligand such as dion bromide. The roughly refined protein specific to the rheumatism is passed through a column in which said gel is packed. The protein specific to the rheumatism is separated by a method for cleaning the column, then changing the pH by a glycine buffer soln., etc. The separated protein is recovered and the intended protein is obtd. The protein obtd. in such a manner exhibits 7.3-7.8 isoelectric point and 0.30-0.45 range of mobility in the stage of two-dimensional electrophoresis and exhibits 150,000-170,000mol.wt. in SDS polyacrylamide gel electrophoresis.
FIELD: medicine, endocrinology, pharmacy. SUBSTANCE: invention describes a novel derivative of insulin with amino acid sequence: SEQ ID NO : 2   where Xaa in positions A21 and B3 are any independent amino acid residues that can be encoded by genetic code with exception for Lys, Arg, Cys; Xaa in position B1 is Phe but this residue can be removed; Xaa in position B30 is (a) any amino acid residue that can be encoded by genetic code with exception for Lys, Arg, Cys and in this case ε-amino-group of Lys B29  has lipophilic substituent or (b) this group is removed and ε-amino-group of Lys B29  in this case has lipophilic substituent; and its any complexes with Zn 2+  under condition that when Xaa in position B30 both are Thr, Ala and Xaa in position A21 and B3 both are Asn and Xaa in position B1 are Phe then insulin derivative is Zn 2+ -complex. Invention relates to also the soluble prolonged pharmaceutical composition based on thereof and method of prolongation of hypoglycaemic effect. Invention can be used for treatment of diabetic patients. EFFECT: new insulin derivative indicated above, valuable medicinal properties. 20 cl, 1 tbl, 3 dwg, 44 ex
PURPOSE: To obtain a composite resin for a dentistry having easily handleable excellent operability before polymerizing and curing, having high mechanical strength, readily polishing of the surface, and having excellent beautifulness, surface gloss and slipperiness, and a low thermal expansion coefficient after polymerizing and curing. CONSTITUTION: This composite resin is composed of a pasty polymerizable composition of 10-40 pts.wt. of a polymerizable monomer containing a polymerization initiator and 90-60 pts.wt. of a mixed filler comprising spherical fillers of synthetic quartz synthesized by a V.M.C. method, organic-inorganic composite fillers and a polymerization initiator. A weight ratio of the spherical filler of synthetic quartz to the organic-inorganic composite filler is (80:20) to (20:80).